Revision of Hip or Knee Replacement with CC DRG Reimbursement

DRG 467 encompasses revision hip or knee replacement procedures complicated by a Complication or Comorbidity, reflecting higher resource intensity than uncomplicated revisions. Understanding this Diagnosis-Related Group is important for inpatient reimbursement because coding and documented comorbid conditions influence Centers for Medicare & Medicaid Services payment levels.

DRG 467 Overview

DRG 467 covers inpatient stays for revision of hip or knee replacement procedures when a Complication or Comorbidity is present. This Diagnosis-Related Group includes cases involving surgical replacement or modification of previously implanted hip or knee prostheses complicated by additional clinical conditions that increase resource use. It matters for Centers for Medicare & Medicaid Services payment because the presence of a Complication or Comorbidity elevates relative weights and reimbursement compared with uncomplicated revisions. Accurate coding of the underlying diagnosis and associated Complication or Comorbidity affects payment and hospital case mix.

DRG 467 Overview

Perioperative infection prevention and management studies: randomized or observational studies evaluating interventions such as enhanced perioperative antiseptic protocols, antibiotic timing/duration strategies, or debridement-with-component-retention versus staged explant approaches for prosthetic joint infection in patients undergoing revision hip or knee arthroplasty. These trials focus on patients presenting for revision due to suspected or confirmed infection, including those with comorbidities like diabetes or obesity that increase infection risk, and they measure outcomes such as eradication of infection, reoperation rates, length of stay, and complication-related costs. This research is highly relevant to surgeons and payers because infection is a leading driver of morbidity, prolonged hospitalization, and readmissions in DRG 467 patients, so evidence that reduces infection-related resource use directly impacts quality metrics and reimbursement risk.
Comparative effectiveness trials of implant and fixation strategies for aseptic loosening and mechanical failure: prospective cohort studies or randomized trials comparing modular revision implants, constrained versus nonconstrained prostheses, cemented versus cementless fixation, or use of augments and porous metaphyseal cones in patients undergoing revision for instability, wear, or loosening. These studies enroll older adults with variable bone loss patterns and aim to assess functional outcomes, revision-free survival, perioperative complications, and cost-effectiveness over 1–5 years. For hospitals and payers, these data inform device selection and supply decisions that affect operative time, implant costs, re-revision rates, and long-term episode costs within the DRG payment framework.
Post-discharge care pathway and rehabilitation outcome studies: pragmatic trials and observational registries testing differing post-acute care strategies such as early intensive outpatient physical therapy versus home-based programs, standardized discharge criteria, or coordinated infection-monitoring follow-up for patients after revision hip or knee arthroplasty. These studies target the heterogeneous post-op population—often older with multiple comorbidities and variable social support—and measure readmissions, functional recovery, patient-reported outcomes, and downstream utilization including skilled nursing facility use. Results are pertinent to clinicians and payers because optimizing discharge planning and rehabilitation can shorten length of stay, reduce readmissions and downstream expenditures, and improve recovery trajectories for patients classified under DRG 467.

Perioperative infection prevention and management studies: randomized or observational studies evaluating interventions such as enhanced perioperative antiseptic protocols, antibiotic timing/duration strategies, or debridement-with-component-retention versus staged explant approaches for prosthetic joint infection in patients undergoing revision hip or knee arthroplasty. These trials focus on patients presenting for revision due to suspected or confirmed infection, including those with comorbidities like diabetes or obesity that increase infection risk, and they measure outcomes such as eradication of infection, reoperation rates, length of stay, and complication-related costs. This research is highly relevant to surgeons and payers because infection is a leading driver of morbidity, prolonged hospitalization, and readmissions in DRG 467 patients, so evidence that reduces infection-related resource use directly impacts quality metrics and reimbursement risk.
Comparative effectiveness trials of implant and fixation strategies for aseptic loosening and mechanical failure: prospective cohort studies or randomized trials comparing modular revision implants, constrained versus nonconstrained prostheses, cemented versus cementless fixation, or use of augments and porous metaphyseal cones in patients undergoing revision for instability, wear, or loosening. These studies enroll older adults with variable bone loss patterns and aim to assess functional outcomes, revision-free survival, perioperative complications, and cost-effectiveness over 1–5 years. For hospitals and payers, these data inform device selection and supply decisions that affect operative time, implant costs, re-revision rates, and long-term episode costs within the DRG payment framework.
Post-discharge care pathway and rehabilitation outcome studies: pragmatic trials and observational registries testing differing post-acute care strategies such as early intensive outpatient physical therapy versus home-based programs, standardized discharge criteria, or coordinated infection-monitoring follow-up for patients after revision hip or knee arthroplasty. These studies target the heterogeneous post-op population—often older with multiple comorbidities and variable social support—and measure readmissions, functional recovery, patient-reported outcomes, and downstream utilization including skilled nursing facility use. Results are pertinent to clinicians and payers because optimizing discharge planning and rehabilitation can shorten length of stay, reduce readmissions and downstream expenditures, and improve recovery trajectories for patients classified under DRG 467.

OpenPayer

Revision of Hip or Knee Replacement with CC: Inpatient Reimbursement Overview

Sign up for drg 467 policy alerts

DRG 467 Overview

OpenPayer

Revision of Hip or Knee Replacement with CC: Inpatient Reimbursement Overview

Sign up for drg 467 policy alerts

DRG 467 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References